Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer

Lucas Goense, Kenneth W. Merrell, Andrea L. Arnett, Christopher Hallemeier, Gert J. Meijer, Jelle P. Ruurda, Wayne L. Hofstetter, Richard van Hillegersberg, Steven H. Lin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Recently, a nomogram was developed for the prediction of overall survival (OS) after treatment with neoadjuvant chemoradiotherapy (nCRT) combined with surgery for esophageal or junctional cancer. The nomogram included clinical nodal category, pathologic tumor category, and number of positive lymph nodes in the resection specimen. The aim of this study was to externally validate the nomogram in an international multiinstitutional cohort of patients, and to explore the prognostic use of the nomogram for the prediction of progression-free survival (PFS) after nCRT plus surgery. Methods: Patients with potentially resectable esophageal or junctional carcinoma that underwent nCRT plus surgery between 1998 and 2015 at 3 academic centers were included. The discriminative ability of the nomogram for the prediction of OS and PFS was quantified by Harrell's C-statistic. Calibration of the nomogram was visually assessed by plotting actual OS and PFS probabilities against predicted probabilities. Results: Some 975 patients were included. The discriminative ability of the nomogram for OS was moderate (C-statistic, 0.61) and comparable to that of the initial cohort (C-statistic, 0.63). The nomogram was also useful for the prediction of PFS (C-statistic, 0.64). Calibration of the nomogram was accurate for both OS and PFS, with predicted estimates corresponding closely with the actual observed estimates. Conclusions: The nomogram accurately predicted OS and PFS after nCRT plus surgery in an independent international cohort of esophageal cancer patients. The current validated model may enable risk-stratified adjuvant treatment allocation and identify patients in need of routine surveillance after treatment.

Original languageEnglish (US)
Pages (from-to)1541-1547
Number of pages7
JournalAnnals of Thoracic Surgery
Volume106
Issue number5
DOIs
StatePublished - Nov 1 2018

Fingerprint

Nomograms
Esophageal Neoplasms
Survival
Disease-Free Survival
Chemoradiotherapy
Therapeutics
Calibration
Neoadjuvant Therapy
Neoplasms
Lymph Nodes
Carcinoma

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. / Goense, Lucas; Merrell, Kenneth W.; Arnett, Andrea L.; Hallemeier, Christopher; Meijer, Gert J.; Ruurda, Jelle P.; Hofstetter, Wayne L.; van Hillegersberg, Richard; Lin, Steven H.

In: Annals of Thoracic Surgery, Vol. 106, No. 5, 01.11.2018, p. 1541-1547.

Research output: Contribution to journalArticle

Goense, L, Merrell, KW, Arnett, AL, Hallemeier, C, Meijer, GJ, Ruurda, JP, Hofstetter, WL, van Hillegersberg, R & Lin, SH 2018, 'Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer', Annals of Thoracic Surgery, vol. 106, no. 5, pp. 1541-1547. https://doi.org/10.1016/j.athoracsur.2018.05.055
Goense, Lucas ; Merrell, Kenneth W. ; Arnett, Andrea L. ; Hallemeier, Christopher ; Meijer, Gert J. ; Ruurda, Jelle P. ; Hofstetter, Wayne L. ; van Hillegersberg, Richard ; Lin, Steven H. / Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer. In: Annals of Thoracic Surgery. 2018 ; Vol. 106, No. 5. pp. 1541-1547.
@article{8eb7b504055545df851ccbb6911580a1,
title = "Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer",
abstract = "Background: Recently, a nomogram was developed for the prediction of overall survival (OS) after treatment with neoadjuvant chemoradiotherapy (nCRT) combined with surgery for esophageal or junctional cancer. The nomogram included clinical nodal category, pathologic tumor category, and number of positive lymph nodes in the resection specimen. The aim of this study was to externally validate the nomogram in an international multiinstitutional cohort of patients, and to explore the prognostic use of the nomogram for the prediction of progression-free survival (PFS) after nCRT plus surgery. Methods: Patients with potentially resectable esophageal or junctional carcinoma that underwent nCRT plus surgery between 1998 and 2015 at 3 academic centers were included. The discriminative ability of the nomogram for the prediction of OS and PFS was quantified by Harrell's C-statistic. Calibration of the nomogram was visually assessed by plotting actual OS and PFS probabilities against predicted probabilities. Results: Some 975 patients were included. The discriminative ability of the nomogram for OS was moderate (C-statistic, 0.61) and comparable to that of the initial cohort (C-statistic, 0.63). The nomogram was also useful for the prediction of PFS (C-statistic, 0.64). Calibration of the nomogram was accurate for both OS and PFS, with predicted estimates corresponding closely with the actual observed estimates. Conclusions: The nomogram accurately predicted OS and PFS after nCRT plus surgery in an independent international cohort of esophageal cancer patients. The current validated model may enable risk-stratified adjuvant treatment allocation and identify patients in need of routine surveillance after treatment.",
author = "Lucas Goense and Merrell, {Kenneth W.} and Arnett, {Andrea L.} and Christopher Hallemeier and Meijer, {Gert J.} and Ruurda, {Jelle P.} and Hofstetter, {Wayne L.} and {van Hillegersberg}, Richard and Lin, {Steven H.}",
year = "2018",
month = "11",
day = "1",
doi = "10.1016/j.athoracsur.2018.05.055",
language = "English (US)",
volume = "106",
pages = "1541--1547",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer

AU - Goense, Lucas

AU - Merrell, Kenneth W.

AU - Arnett, Andrea L.

AU - Hallemeier, Christopher

AU - Meijer, Gert J.

AU - Ruurda, Jelle P.

AU - Hofstetter, Wayne L.

AU - van Hillegersberg, Richard

AU - Lin, Steven H.

PY - 2018/11/1

Y1 - 2018/11/1

N2 - Background: Recently, a nomogram was developed for the prediction of overall survival (OS) after treatment with neoadjuvant chemoradiotherapy (nCRT) combined with surgery for esophageal or junctional cancer. The nomogram included clinical nodal category, pathologic tumor category, and number of positive lymph nodes in the resection specimen. The aim of this study was to externally validate the nomogram in an international multiinstitutional cohort of patients, and to explore the prognostic use of the nomogram for the prediction of progression-free survival (PFS) after nCRT plus surgery. Methods: Patients with potentially resectable esophageal or junctional carcinoma that underwent nCRT plus surgery between 1998 and 2015 at 3 academic centers were included. The discriminative ability of the nomogram for the prediction of OS and PFS was quantified by Harrell's C-statistic. Calibration of the nomogram was visually assessed by plotting actual OS and PFS probabilities against predicted probabilities. Results: Some 975 patients were included. The discriminative ability of the nomogram for OS was moderate (C-statistic, 0.61) and comparable to that of the initial cohort (C-statistic, 0.63). The nomogram was also useful for the prediction of PFS (C-statistic, 0.64). Calibration of the nomogram was accurate for both OS and PFS, with predicted estimates corresponding closely with the actual observed estimates. Conclusions: The nomogram accurately predicted OS and PFS after nCRT plus surgery in an independent international cohort of esophageal cancer patients. The current validated model may enable risk-stratified adjuvant treatment allocation and identify patients in need of routine surveillance after treatment.

AB - Background: Recently, a nomogram was developed for the prediction of overall survival (OS) after treatment with neoadjuvant chemoradiotherapy (nCRT) combined with surgery for esophageal or junctional cancer. The nomogram included clinical nodal category, pathologic tumor category, and number of positive lymph nodes in the resection specimen. The aim of this study was to externally validate the nomogram in an international multiinstitutional cohort of patients, and to explore the prognostic use of the nomogram for the prediction of progression-free survival (PFS) after nCRT plus surgery. Methods: Patients with potentially resectable esophageal or junctional carcinoma that underwent nCRT plus surgery between 1998 and 2015 at 3 academic centers were included. The discriminative ability of the nomogram for the prediction of OS and PFS was quantified by Harrell's C-statistic. Calibration of the nomogram was visually assessed by plotting actual OS and PFS probabilities against predicted probabilities. Results: Some 975 patients were included. The discriminative ability of the nomogram for OS was moderate (C-statistic, 0.61) and comparable to that of the initial cohort (C-statistic, 0.63). The nomogram was also useful for the prediction of PFS (C-statistic, 0.64). Calibration of the nomogram was accurate for both OS and PFS, with predicted estimates corresponding closely with the actual observed estimates. Conclusions: The nomogram accurately predicted OS and PFS after nCRT plus surgery in an independent international cohort of esophageal cancer patients. The current validated model may enable risk-stratified adjuvant treatment allocation and identify patients in need of routine surveillance after treatment.

UR - http://www.scopus.com/inward/record.url?scp=85054033313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054033313&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2018.05.055

DO - 10.1016/j.athoracsur.2018.05.055

M3 - Article

C2 - 29932887

AN - SCOPUS:85054033313

VL - 106

SP - 1541

EP - 1547

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 5

ER -